Fierce Biotech June 10, 2024
Conor Hale

Abbott’s diabetes division thought joining the over-the-counter market looked so nice they did it twice. The company has collected FDA clearances for two separate continuous glucose monitoring systems, the Libre Rio and the Lingo.

Both are built off Abbott’s mainstay wearable CGM, the FreeStyle Libre. While the Libre Rio is designed for adults with Type 2 diabetes who are not taking insulin—but who may be taking medications such as GLP-1s—the Lingo carries a more general “health and wellness” focus, aimed at providing blood sugar data to the curious consumer.

“There is no one-size-fits-all approach for glucose monitoring, which is why we’ve designed different products for different people—all based on the same world-leading biowearable technology,” Lisa Earnhardt, president of Abbott’s...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, FDA, Govt Agencies, Medical Devices, Technology, Wearables
Danaher setting up labs to support companion diagnostic development
Q Bio Secures $27M to Expand Full-Body MRI with Mark I Scanner
Advanced diagnostics: Patient-centered innovation
Abbott previews PFA, over-the-counter CGM markets
STAT+: Startup Q Bio raises $27 million to build its own full-body scanner

Share This Article